Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment and self-reported side effects in the euthymic phase of bipolar disorders: Results from the FACE-BD cohort
N. Vidal
(1, 2, 3)
,
E. Brunet-Gouet
(1, 2, 3)
,
S. Frileux
(1, 2, 3)
,
B. Aouizerate
(1, 4, 5)
,
V. Aubin
(6, 1)
,
R. Belzeaux
(7, 8, 1)
,
P. Courtet
(8, 1, 9)
,
T. d'Amato
(1, 10)
,
C. Dubertret
(1, 11, 12)
,
B. Etain
(1, 13, 14)
,
E. Haffen
(15, 1, 16)
,
D. Januel
(1, 17)
,
M. Leboyer
(1, 18, 19)
,
A. Lefrere
(1, 20, 7)
,
P.M. Llorca
(1, 21, 22)
,
E. Marlinge
(1, 13, 14)
,
Émilie Olié
(8, 1, 9)
,
M. Polosan
(23, 24, 1)
,
R. Schwan
(25, 1, 26)
,
M. Walter
(27, 8, 1)
,
C. Passerieux
(1)
,
P. Roux
(1)
,
B. Etain
(1)
,
E. Olié
(1)
,
M. Leboyer
(1)
,
E. Haffen
(1)
,
P.M. Llorca
(1)
,
V. Barteau
(1)
,
S. Bensalem
(1)
,
O. Godin
(1)
,
H. Laouamri
(1)
,
K. Souryis
(1)
,
S. Hotier
(1)
,
A. Pelletier
(1)
,
N. Drancourt
(1)
,
J.P. Sanchez
(1)
,
E. Saliou
(1)
,
C. Hebbache
(1)
,
J. Petrucci
(1)
,
L. Willaume
(1)
,
E. Bourdin
(1)
,
F. Bellivier
(1)
,
M. Carminati
(1)
,
B. Etain
(1)
,
E. Marlinge
(1)
,
J. Meheust
(1)
,
V. Hennion
(1)
,
H. Francisque
(1)
,
B. Aouizerate
(1)
,
N. da Ros
(1)
,
A. Desage
(1)
,
C. Elkael
(1)
,
S. Gard
(1)
,
F. Hoorelbeke
(1)
,
K. M'Bailara
(1)
,
I. Minois
(1)
,
J. Sportich
(1)
,
L. Boukhobza
(1)
,
M. Benramdane
(1)
,
P. Courtet
(1)
,
B. Deffinis
(1)
,
S. Denat
(1)
,
D. Ducasse
(1)
,
M. Gachet
(1)
,
F. Molière
(1)
,
L. Nass
(1)
,
E. Olié
(1)
,
G. Tarquini
(1)
,
R. Belzeaux
(1)
,
M. Cermolacce
(1)
,
F. Groppi
(1)
,
E. Moreau
(1)
,
A. Lefrere
(1)
,
L. Lescalier
(1)
,
J. Pastol
(1)
,
N. Viglianese
(1)
,
R. Cohen
(1)
,
G. Gross
(1)
,
R. Schwan
(1)
,
T. Schwitzer
(1)
,
O. Wajsbrot-Elgrabli
(1)
,
T. Bougerol
(1)
,
B. Fredembach
(1)
,
Q Denoual
(1)
,
A. Bertrand
(1)
,
A. Pouchon
(1)
,
M. Polosan
(1)
,
G. Bonny
(1)
,
L. Brehon
(1)
,
L. Durand
(1)
,
V. Feuga
(1)
,
A.M. Galliot
(1)
,
N. Kayser
(1)
,
C. Passerieux
(1)
,
P. Roux
(1)
,
V. Aubin
(1)
,
I. Cussac
(1)
,
M.A. Dupont
(1)
,
J. Loftus
(1)
,
I. Medecin
(1)
,
C. Dubertret
(1)
,
N. Mazer
(1)
,
C. Portalier
(1)
,
C. Scognamiglio
(1)
,
A. Bing
(1)
,
P. Laurent
(1)
,
Pm. Llorca
(1)
,
L. Samalin
(1)
,
L. Foures
(1)
,
D. Lacelle
(1)
,
S. Pires
(1)
,
C. Doriat
(1)
,
O. Blanc
(1)
,
E. Haffen
(1)
,
D. Bennabi
(1)
,
M. Nicolier
(1)
1
Fondation FondaMental [Créteil]
2 CHV - Centre Hospitalier de Versailles André Mignot
3 CESP - Centre de recherche en épidémiologie et santé des populations
4 Centre hospitalier Charles Perrens [Bordeaux]
5 NutriNeuro - Nutrition et Neurobiologie intégrée
6 Centre Hospitalier Princesse Grace
7 INT - Institut de Neurosciences de la Timone
8 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
9 IGF - Institut de Génomique Fonctionnelle
10 CRNL - Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center
11 Hôpital Louis Mourier - AP-HP [Colombes]
12 IPNP - U1266 Inserm - Institut de psychiatrie et neurosciences de Paris
13 Hôpital Lariboisière-Fernand-Widal [APHP]
14 OPTeN (UMR_S 1144 / U1144) - Optimisation thérapeutique en Neuropsychopharmacologie
15 UBFC - Université Bourgogne Franche-Comté [COMUE]
16 Inserm CIC 1431 - Centre d'Investigation Clinique de Besançon
17 EPS - Etablissement public de santé de Ville-Evrard [Neuilly-sur-Marne]
18 IMRB - Institut Mondor de Recherche Biomédicale
19 Hôpital Henri Mondor
20 APHM - Assistance Publique - Hôpitaux de Marseille
21 CHU Clermont-Ferrand
22 NPsy-Sydo - Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux
23 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
24 GIN - [GIN] Grenoble Institut des Neurosciences
25 UL - Université de Lorraine
26 CPN - Centre Psychothérapique de Nancy [Laxou]
27 EA7479 SPURBO - Soins Primaires, Santé Publique, Registre des cancers de Bretagne Occidentale
2 CHV - Centre Hospitalier de Versailles André Mignot
3 CESP - Centre de recherche en épidémiologie et santé des populations
4 Centre hospitalier Charles Perrens [Bordeaux]
5 NutriNeuro - Nutrition et Neurobiologie intégrée
6 Centre Hospitalier Princesse Grace
7 INT - Institut de Neurosciences de la Timone
8 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
9 IGF - Institut de Génomique Fonctionnelle
10 CRNL - Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center
11 Hôpital Louis Mourier - AP-HP [Colombes]
12 IPNP - U1266 Inserm - Institut de psychiatrie et neurosciences de Paris
13 Hôpital Lariboisière-Fernand-Widal [APHP]
14 OPTeN (UMR_S 1144 / U1144) - Optimisation thérapeutique en Neuropsychopharmacologie
15 UBFC - Université Bourgogne Franche-Comté [COMUE]
16 Inserm CIC 1431 - Centre d'Investigation Clinique de Besançon
17 EPS - Etablissement public de santé de Ville-Evrard [Neuilly-sur-Marne]
18 IMRB - Institut Mondor de Recherche Biomédicale
19 Hôpital Henri Mondor
20 APHM - Assistance Publique - Hôpitaux de Marseille
21 CHU Clermont-Ferrand
22 NPsy-Sydo - Neuro-Psycho Pharmacologie des Systèmes Dopaminergiques sous-corticaux
23 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
24 GIN - [GIN] Grenoble Institut des Neurosciences
25 UL - Université de Lorraine
26 CPN - Centre Psychothérapique de Nancy [Laxou]
27 EA7479 SPURBO - Soins Primaires, Santé Publique, Registre des cancers de Bretagne Occidentale
T. d'Amato
- Fonction : Auteur
- PersonId : 1290580
- ORCID : 0000-0001-8983-0315
M. Leboyer
- Fonction : Auteur
- PersonId : 756830
- ORCID : 0000-0001-5473-3697
- IdRef : 089352475
P.M. Llorca
- Fonction : Auteur
- PersonId : 781416
- ORCID : 0000-0001-7438-8990
- IdRef : 05967797X
C. Passerieux
- Fonction : Auteur
- PersonId : 1234382
- ORCID : 0000-0003-4130-1590
O. Godin
- Fonction : Auteur
- PersonId : 1093297
- IdHAL : ophelia-godin
- ORCID : 0000-0001-5004-5475
N. Drancourt
- Fonction : Auteur
- PersonId : 1183954
- ORCID : 0000-0002-3985-4885
Résumé
Bipolar disorders (BD) are characterized by cognitive impairment during the euthymic phase, to which treatments can contribute. The anticholinergic properties of medications, i.e., the ability of a treatment to inhibit cholinergic receptors, are associated with cognitive impairment in elderly patients and people with schizophrenia but this association has not been well characterized in individuals with remitted BD. Moreover, the validity of only one anticholinergic burden scale designed to assess the anticholinergic load of medications has been tested in BD. In a literature review, we identified 31 existing scales. We first measured the associations between 27 out of the 31 scales and objective cognitive impairment in bivariable regressions. We then adjusted the bivariable models with covariates: the scales significantly associated with cognitive impairment in bivariable and multiple logistic regressions were defined as having good concurrent validity to assess cognitive impairment. In a sample of 2,031 individuals with euthymic BD evaluated with a neuropsychological battery, two scales had good concurrent validity to assess cognitive impairment, whereas chlorpromazine equivalents, lorazepam equivalents, the number of antipsychotics, or the number of treatments had not. Finally, similar analyses with subjective anticholinergic side-effects as outcome variables reported 14 scales with good concurrent validity to assess self-reported peripheral anticholinergic side-effects and 13 to assess self-reported central anticholinergic side-effects. Thus, we identified valid scales to monitor the anticholinergic burden in BD, which may be useful in estimating iatrogenic cognitive impairment in studies investigating cognition in BD.